Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Butyl-N-(4-hydroxybutyl)nitrosamine (OH-BBN) is a synthetic nitrosamine and potent carcinogen widely used in experimental models, primarily for the induction of urinary bladder cancer in rodents[1][3][4]. The compound acts through alkylation of cellular DNA, leading to mutations and subsequent oncogenesis. OH-BBN is frequently employed to study carcinogenesis and test chemopreventive agents, such as non-steroidal anti-inflammatory drugs[1]. It is recognized for inducing high-grade, invasive bladder cancers that closely mimic the human disease phenotype and progression[1][2][3]. The chemical is not indicated for human therapeutic use and is highly toxic, classified as a Category 1B carcinogen[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-butyl-n-(4-hydroxybutyl)nitrosamine.